type here...

CATEGORIES

Discover Drugs

LATEST

123Page 3 of 3

TRENDING

EDITORS CHOICE

Alterity and UniQuest Partner to Reverse Bacterial Resistance to Antibiotics

Medika Life -
Alterity has secured the worldwide exclusive right to patented technology to develop and commercialise therapies that re-sensitise bacteria to antibiotics

FDA Approves Drug Combination for Treating Mesothelioma

Medika Life -
First approval in 16 years for mesothelioma, a type of cancer caused by inhaling asbestos fibers SILVER SPRING, Md., Oct. 2, 2020 /PRNewswire/ -- Today, the U.S. Food...

Reblozyl (luspatercept) Approved for Treatment of Transfusion-Dependent Anemia

Medika Life -
European Commission Approves Reblozyl (luspatercept) for the Treatment of Transfusion-Dependent Anemia in Adult Patients with Myelodysplastic Syndromes or Beta Thalassemia

ZEPOSIA® (ozanimod), a New Oral Treatment for Relapsing Forms of Multiple Sclerosis

Medika Life -
ZEPOSIA, a treatment for multiple sclerosis is the first and only approved sphingosine-1-phosphate (S1P) receptor modulator with no genetic test or first dose observation at initiation

CONNECT WITH US ON SOCIAL MEDIA

Medika Life is a unique, not-for-profit operating unit of FINN Partners and maintains an independent voice. Authors opinions may not necessarily represent those shared by FINN Partners and content cannot be promotional - rather informational centered on health issues, life science innovation, ecohealth and patient experience.

© Medika Life 2020 - 2022

Compliance

CORPORATE & MEDIA

Popular categories